Proteomic profiling of serum identifies a molecular signature that correlates with clinical outcomes in COPD

Author:

Dagher Rania,Fogel Paul,Wang Jingya,Soussan David,Chiang Chia-Chien,Kearley Jennifer,Muthas Daniel,Taillé Camille,Berger PatrickORCID,Bourdin Arnaud,Chenivesse Cécile,Leroy Sylvie,Anderson Gary,Humbles Alison A.,Aubier Michel,Kolbeck Roland,Pretolani MarinaORCID,

Abstract

Objective Novel biomarkers related to main clinical hallmarks of Chronic obstructive pulmonary disease (COPD), a heterogeneous disorder with pulmonary and extra-pulmonary manifestations, were investigated by profiling the serum levels of 1305 proteins using Slow Off-rate Modified Aptamers (SOMA)scan technology. Methods Serum samples were collected from 241 COPD subjects in the multicenter French Cohort of Bronchial obstruction and Asthma to measure the expression of 1305 proteins using SOMAscan proteomic platform. Clustering of the proteomics was applied to identify disease subtypes and their functional annotation and association with key clinical parameters were examined. Cluster findings were revalidated during a follow-up visit, and compared to those obtained in a group of 47 COPD patients included in the Melbourne Longitudinal COPD Cohort. Results Unsupervised clustering identified two clusters within COPD subjects at inclusion. Cluster 1 showed elevated levels of factors contributing to tissue injury, whereas Cluster 2 had higher expression of proteins associated with enhanced immunity and host defense, cell fate, remodeling and repair and altered metabolism/mitochondrial functions. Patients in Cluster 2 had a lower incidence of exacerbations, unscheduled medical visits and prevalence of emphysema and diabetes. These protein expression patterns were conserved during a follow-up second visit, and substanciated, by a large part, in a limited series of COPD patients. Further analyses identified a signature of 15 proteins that accurately differentiated the two COPD clusters at the 2 visits. Conclusions This study provides insights into COPD heterogeneity and suggests that overexpression of factors involved in lung immunity/host defense, cell fate/repair/ remodelling and mitochondrial/metabolic activities contribute to better clinical outcomes. Hence, high throughput proteomic assay offers a powerful tool for identifying COPD endotypes and facilitating targeted therapies.

Funder

AstraZeneca USA

Legs Poix - Chancellerie des Universités

Chiesi

GlaxoSmithKline

MedImmune LLC

Novartis Pharma AG

Roche

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference46 articles.

1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary;CF Vogelmeier;Eur Respir J,2017

2. Oxidative, inflammatory, genetic, and epigenetic biomarkers associated with chronic obstructive pulmonary disorder;T Aggarwal;J Cell Physiol,2019

3. Lung ageing and COPD: is there a role for ageing in abnormal tissue repair?;C-A Brandsma;Eur Respir Rev,2017

4. Senescence in COPD and Its Comorbidities;PJ Barnes;Annu Rev Physiol,2017

5. Chronic obstructive pulmonary disease subpopulations and phenotyping;LN Segal;J. Allergy Clin Immunol,2018

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Disease Endotypes Predict the Severity of Mucous Membrane Pemphigoid;Journal of Investigative Dermatology;2023-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3